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Abstract
Male breast cancer accounts for approximately 1% of all breast cancer. To date, risk factors for male breast cancer are poorly
defined, but certain risk factors and genetic features appear common to both male and female breast cancer. Genome-wide
association studies (GWAS) have recently identified common single nucleotide polymorphisms (SNPs) that influence female
breast cancer risk; 12 of these have been independently replicated. To examine if these variants contribute to male breast
cancer risk, we genotyped 433 male breast cancer cases and 1,569 controls. Five SNPs showed a statistically significant
association with male breast cancer: rs13387042 (2q35) (odds ratio (OR) = 1.30, p = 7.9861024), rs10941679 (5p12)
(OR= 1.26, p = 0.007), rs9383938 (6q25.1) (OR= 1.39, p = 0.004), rs2981579 (FGFR2) (OR = 1.18, p = 0.03), and rs3803662
(TOX3) (OR = 1.48, p = 4.0461026). Comparing the ORs for male breast cancer with the published ORs for female breast
cancer, three SNPs—rs13387042 (2q35), rs3803662 (TOX3), and rs6504950 (COX11)—showed significant differences in ORs
(p,0.05) between sexes. Breast cancer is a heterogeneous disease; the relative risks associated with loci identified to date
show subtype and, based on these data, gender specificity. Additional studies of well-defined patient subgroups could
provide further insight into the biological basis of breast cancer development.
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Introduction
Breast cancer does not exclusively affect females. Around 300
men in the UK and 1,900 men in the US are diagnosed with the
disease each year [1]. The average age at incidence of male breast
cancer is somewhat different to that seen for female breast cancer,
with the disease typically affecting men 5–10 years later than
women. Perhaps because male breast cancer is not common, few
risk factors have been demonstrated to influence disease risk, but
tentative associations with obesity, lack of exercise, excess alcohol
consumption, gynaecomastia, past benign breast disease, past liver
disease, infertility, diabetes and exposure to ionising radiation have
been suggested [2,3].
Investigation of susceptibility genes for male breast cancer has
been limited. It has however been shown that approximately 10%
of men with breast cancer carry BRCA2 mutations, while
mutations in BRCA1 are exceedingly rare [4]. The relative risk
of breast cancer in men associated with BRCA2 mutations is high
[5]. Recently the CHEK2 1100delC variant has been found to give
a 10-fold risk of male breast cancer independent of BRCA1 or
BRCA2 [6]. Mutations in these genes are rare in the general
population and it is likely that much of the genetic contribution to
female breast cancer risk can be attributed to the co-inheritance of
multiple low risk common variants [7]. Recent genome-wide
association studies (GWAS) have shown associations between
single nucleotide polymorphisms (SNPs) mapping to a dozen or
more loci and female breast cancer risk in European populations,
each conferring odds ratios (ORs) of 1.04–1.43 [8–14]. To explore
the possibility that the same risk variants influence male breast
cancer risk, we conducted a case-control study of male breast
cancer, genotyping 12 SNPs annotating the loci that have the
strongest and most consistent associations with female breast
cancer.
Materials and Methods
457 cases of male breast cancer were recruited in a population-
based case-control study of the genetic, environmental and
behavioral causes of male breast cancer being conducted in
England and Wales. Potential cases were all men resident in these
countries aged 18–79 with newly diagnosed breast cancer since
January 1st, 2005, identified through notifications by treatment
centres and systematic regular listings of cases from regional
cancer registries. 98% of cases for whom registry data has been
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received have been histologically confirmed. The median age at
diagnosis of cases was 65.5 years (interquartile range: 59–72).
A total of 1608 unmatched controls were available for
genotyping; 535 men were ascertained through our ongoing
breast cancer studies and a further 1073 were healthy male and
female individuals from the UK Genetic Lung Cancer Predispo-
sition Study (GELCAPS) [15]. The decision to include a second
control set was made a priori, with the aim of increasing statistical
power. We saw no evidence for an effect of control group on the
overall effect estimate for each SNP. Collection of blood samples
from all subjects was undertaken with informed consent and
relevant ethical review committee approval.
DNAwas extracted from venous blood samples using conventional
methodologies and quantified by Picogreen (Invitrogen, Carlsbad
CA). SNPs were chosen for analysis on the basis of validated
associations with female breast cancer from recent GWAS [8–14].
Genotyping of rs11249433, rs13387042, rs4973768, rs10941679,
rs16886165, rs9383938, rs13281615, rs865686, rs2981579,
rs3817198, rs3803662 and rs6504950 was performed by allele-
specific PCR using KASPar chemistry (Kbioscience, Hertfordshire,
UK). Each DNA plate contained 5% sample duplication to assess
genotyping concordance between duplicate pairs. We attempted to
genotype 2119 samples (including duplicates, n=54) and excluded
samples (n=49; 11 cases, 34 controls and four members of a
duplicate pair) in which no-calls were observed for two or more SNPs.
Genotyping QC statistics were therefore computed on 2070 samples
(Figure S1). Final locus and sample completion rates were .99.9%.
The mean genotype concordance between duplicate pairs was
99.8%. We excluded a further 18 subjects due to self-reported non-
European ancestry (13 cases and 5 controls). No SNP genotypes
showed significant deviation from the proportions expected under
Hardy-Weinberg equilibrium in controls (Table S1).
ORs and 95% confidence intervals (CI) were calculated using
unconditional logistic regression. The odds ratio for each SNP was
determined by fitting multiplicative and unconstrained genetic
models. P-values were computed from likelihood ratio test
statistics. Case-only unconditional logistic regression was used to
test the significance of association with age at diagnosis. Deviation
of genotype proportions from Hardy-Weinberg equilibrium was
assessed in controls using an exact test [16]. To compare formally
the ORs in males with the equivalent published ORs for female
disease, we assumed both sets of ORs were log-normally
distributed. Then under the null hypothesis that the OR in males
is equal to the OR in females, the difference between the estimated
log ORs is normally distributed with mean zero and variance
equal to the sum of the squared standard errors of the two
estimates. From this we obtained a x2 statistic for each comparison
(1 degree of freedom [d.f.]) and from the sum of the x2 statistics a
global test for all comparisons (12 d.f.). Statistical analyses were
performed using the Genotype Libraries and Utilities (GLU)
package (http://code.google.com/p/glu-genetics) and R [17].
Results/Discussion
433 male breast cancer cases and 1569 controls were
successfully genotyped according to our predefined QC criteria.
The majority of cases were diagnosed with invasive breast cancer
(n = 399 (92%)) while a further 31 (7%) were ductal carcinoma in
situ. Three cases (,1%) were of unknown histology. Table 1 shows
the OR for male breast cancer associated with each of the 12 SNPs
previously reported to be associated with female breast cancer risk.
For five SNPs, rs13387042 (2q35), rs10941679 (5p12), rs9383938
(6q25.1), rs2981579 (FGFR2) and rs3803662 (TOX3), the risk allele
for female breast cancer was associated with increased risk of male
breast cancer (p,0.05). Two SNPs, rs13387042 (2q35) and
rs3803662 (TOX3), remained significant below the Bonferroni
adjusted threshold for independent tests of p,4.1261023.
Comparing ORmale estimates with those for female breast
cancer (ORfemale) there were two SNPs, rs13387042 (2q35) and
rs3803882 (TOX3) for which the ORmale was significantly higher
than the ORfemale, albeit not after adjusting for multiple testing
(rs13387042, ORmale:ORfemale p = 0.03; rs3803882, ORmale:
ORfemale p = 0.04; Table 2). rs3803662 (TOX3) showed the
strongest association with male breast cancer (ORmale = 1.48;
95% CI 1.26–1.75, p = 4.0461026) with an excess relative risk
that was more than twice the female estimate (ORfemale = 1.20;
95% CI 1.16–1.24) [9]. Similarly, the excess risk conferred by
rs13387042 (2q35) in males (ORmale = 1.30; 95% CI 1.11–1.51,
p = 7.9861024) was more than double that observed in females
(ORfemale = 1.12; 95% CI 1.09–1.15) [11].
For one SNP (rs6504950, COX11) the ORmale was in the
opposite direction to that reported for female breast cancer
(ORmale = 0.90; 95% CI 0.76–1.06, ORfemale = 1.05; 95% CI
1.03–1.07) [8,9] and was inconsistent with the female estimate
(ORmale:ORfemale p = 0.04; Table 2). For the other nine SNPs that
we tested the ORmale estimates were consistent with the ORfemale
estimates. Comparing the combined estimates of all 12 SNPs,
however, there was nominal evidence that the male ORs differed
from the female ORs (p= 0.03; Table 2).
The frequency of female breast tumors that are estrogen receptor
(ER) positive varies, particularly according to menopausal status at
diagnosis [18]. Based on a sample of almost 3,000 patients the
proportion is typically between 64% and 79% [18]. In contrast,
male breast tumors, tend to be overwhelmingly ER-positive (.90%)
[19]. In the current study estrogen receptor status was known for
251 male breast cancer cases, 246 (98%) of which had ER-positive
tumors. For nine of the 12 SNPs that we genotyped, ORfemale
estimates stratified according to ER status have been reported for
Caucasian populations (Tables S2a and S2b). In females, the OR
for ER-positive disease is stronger than the OR for ER-negative
disease for all nine of these loci and this difference is significant for
all but two of them (rs16886165 (MAP3KI) and rs3817198 (LSP1)
[8,11,20]. Given the predominance of ER-positive tumors in male
disease we also compared the ORmale with the ORfemale for ER-
positive disease (Table S2a). There was nominally significant
evidence overall that the male ORs differed from those for ER-
positive female disease (p= 0.05). We also tested for a difference
between the ORmale estimates for these nine SNPs and the ORfemale
estimates for ER-negative disease (Table S2b); there was stronger
evidence of a difference (p= 0.01).
Finally, we assessed the relationship between genotype and age
at onset of male breast cancer (Table S3) for each of the 12 loci.
There was no evidence for a trend with age at diagnosis.
Author Summary
Breast cancer is the most common female cancer in the
United Kingdom but also occurs in men, albeit at a much
lower frequency. Relatively little is known regarding risk
factors for male breast cancer. Here, we examine the effect
of common genetic variants that are known to be associated
with female breast cancer to determine whether they also
affect risk of male breast cancer. We show that certain of
these variants are also associated withmale breast cancer risk
but that the magnitudes of their effects differ in males from
females. Future analyses of the genetics of male breast
cancer may shed light on the biology of both male and
female breast cancer.
Common Genetic Variants and Male Breast Cancer
PLoS Genetics | www.plosgenetics.org 2 September 2011 | Volume 7 | Issue 9 | e1002290
We have shown, for the first time that common genetic variants
influence susceptibility to male breast cancer. Furthermore we have
demonstrated that for at least a subset of known susceptibility loci the
risk allele for female breast cancer is also associated with increased
risk of disease in males. To our knowledge these 433 male breast
cancer cases represent the largest single series to date; despite this, we
lacked power to detect modest relative risks for all but the most
common variants. For example we had only 40% power to detect an
OR of 1.15 for a variant with a minor allele frequency of 30% at a
significance level of 5%. The lack of a statistically significant
association with male breast cancer risk for seven of the 12 SNPs
that we tested may, therefore, simply reflect a lack of power.
Notably, for two of the three SNPs for which the ORmale was
inconsistent with the ORfemale (rs13387042 (2q35) and rs3803882
(TOX3)) the association in males was stronger than that in females.
While the ORmale estimates were slightly closer to the ORs for ER-
positive disease in females, it is noticeable that these are the two SNPs
that show the largest effects on ER-negative disease risk in females.
Although the significance of this observation, if any, is not yet clear, our
data on male breast cancer alongside the published associations with
female breast cancer, clearly implicate the 2q35 and 16q12.1 loci in the
aetiology of breast cancer, irrespective of gender and tumor pathology.
Given that the majority of female breast cancer risk loci
identified to date demonstrate a degree of specificity for ER-
positive or ER-negative disease [8,11,20,21] it seems likely that
Table 1. Risk estimates for male breast cancer conferred by 12 loci identified through GWAS of female breast cancer.
SNP Chromosome Gene
Risk
Allelea
Risk Allele
Freq Male breast cancer Female breast cancer
b
OR(het) OR(hom) OR(trend) P(trend) OR(trend) P(trend)
rs11249433 1p11.2 NOTCH2 C 0.42 1.07 1.28 1.12 0.13 1.20 [13] 4.48210213
(0.84–1.36) (0.94–1.73) (0.97–1.31) (1.14–1.25)
rs13387042 2q35 A 0.50 1.31 1.69 1.30 7.98210204 1.12 [11] 1.00210219
(1.00–1.73) (1.24–2.29) (1.11–1.51) (1.09–1.15)
rs4973768 3p24.1 SLC4A7 T 0.47 1.05 1.28 1.13 0.11 1.11 [8] 1.40210218
(0.81–1.36) (0.95–1.74) (0.97–1.32) (1.08–1.13)
rs10941679 5p12 G 0.27 1.28 1.54 1.26 0.007 1.19 [12] 2.90210211
(1.02–1.60) (1.04–2.29) (1.07–1.48) (1.13–1.26)
rs16886165 5q11.2 MAP3K1 G 0.16 0.99 0.85 0.97 0.77 1.23 [13] 5.00210207
(0.78–1.26) (0.41–1.78) (0.79–1.19) (1.12–1.35)
rs9383938 6q25.1 ESR1 T 0.09 1.31 2.79 1.39 0.01 1.18 [10] 1.41210207
(0.99–1.73) (1.11–7.00) (1.09–1.78) (1.11–1.26)
rs13281615 8q24.21 G 0.41 0.97 1.20 1.07 0.37 1.08 [9] 5.00210212
(0.76–1.23) (0.88–1.64) (0.92–1.25) (1.05–1.11)
rs865686 9q31.2 T 0.62 1.07 1.10 1.04 0.62 1.11 [10] 1.75210210
(0.77–1.49) (0.78–1.53) (0.89–1.22) (1.04 -1.19)
rs2981579 10q26.13 FGFR2 T 0.42 1.06 1.43 1.18 0.03 1.26 [9,14] 2.00210276
(0.83–1.36) (1.06–1.94) (1.02–1.38) (1.23–1.30)
rs3817198 11p15.5 LSP1 C 0.32 0.94 0.87 0.93 0.39 1.07 [9] 3.00210209
(0.75–1.89) (0.60–1.25) (0.79–1.09) (1.04 -1.11)
rs3803662 16q12.1 TOX3 T 0.27 1.48 2.21 1.48 4.04210206 1.20 [9] 1.00210236
(1.18–1.85) (1.50–3.25) (1.26–1.75) (1.16–1.24)
rs6504950 17q22 COX11 G 0.72 0.86 0.79 0.90 0.22 1.05 [8] 1.40610208
(0.58–1.28) (0.53–1.17) (0.76–1.06) (1.03–1.07)
aRisk allele for female breast cancer.
bFemale association statistics and effect estimates from previously published data.
doi:10.1371/journal.pgen.1002290.t001
Table 2. Ratio of ORmale:ORfemale for 12 risk loci identified by
genome-wide association studies of female breast cancer.
SNP Chromosome
ORmale:ORfemale
(95% CI) x2 P-valuea
rs11249433 1p11.2 0.95 (0.80–1.11) 0.425 0.50
rs13387042 2q35 1.19 (1.01–1.39) 4.538 0.03
rs4973768 3p24.1 1.07 (0.91–1.25) 0.681 0.41
rs10941679 5p12 1.03 (0.86–1.22) 0.087 0.77
rs16886165 5q11.2 0.81 (0.65–1.02) 3.116 0.08
rs9383938 6q25.1 1.22 (0.95–1.58) 2.400 0.12
rs13281615 8q24.21 1.02 (0.87–1.20) 0.036 0.85
rs865686 9q31.2 0.95 (0.80–1.13) 0.293 0.59
rs2981579 10q26.13 0.96 (0.82–1.12) 0.315 0.57
rs3817198 11p15.5 0.87 (0.74–1.03) 2.646 0.10
rs3803662 16q12.1 1.19 (1.01–1.42) 4.118 0.04
rs6504950 17q22 0.84 (0.71–0.99) 4.086 0.04
All SNPs combined 22.769 0.03
aP value for null hypothesis of no difference between ORmale and ORfemale for
each SNP individually and for all SNPs combined (in bold).
doi:10.1371/journal.pgen.1002290.t002
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subtype specific GWAS will lead to the identification of additional
risk loci. Our analyses suggest that GWAS of male breast cancer
may also lead to the identification of novel breast cancer risk loci
in males and that these should provide further insight into the
biological basis of male and female breast cancer development.
Supporting Information
Figure S1 Sample exclusion schema.
(DOCX)
Table S1 P values for exact test of deviation from genotype
proportions expected under Hardy-Weinberg equilibrium in
controls.
(DOCX)
Table S2 Ratio of OR estimate for male breast cancer and OR
estimate for a) estrogen receptor positive female breast cancer and
for b) estrogen receptor negative female breast cancer for nine
SNPs for which stratified estimates have been reported.
(DOCX)
Table S3 Odds ratios and 95% confidence intervals for each
locus modeled multiplicatively in cases aged less than 60 years
(n = 119), between 60 and 69 years (n = 153) and cases aged 70
years and greater (n = 161) versus all controls (n = 1569).
(DOCX)
Acknowledgments
We thank the men who participated in the study. We are grateful for
administrative help and advice to Beverley Smith, Deborah Hogben,
Robert McCann, Jane Melia, Sharon Squires, Margaret Snigorska, Joanne
Micic, and Kim Sibley; to the research nurses Alison Butlin, Margo
Pelerin, Jill Wood, and Tracy Gardener for collection of blood samples and
questionnaire data from participants; and to Dawn Thomas and her team
from the BGS Study for coordinating collection of controls. We are grateful
for the support of the cancer registries of England and Wales in providing
us with information on eligible participants. Finally, we wish to thank the
consultants under whose care the patients were for their advice and help.
Author Contributions
Conceived and designed the experiments: NO AA AS. Performed the
experiments: SC-B KT. Analyzed the data: NO RC OF FD. Contributed
reagents/materials/analysis tools: RC MJ PB RH AA AS. Wrote the
paper: NO OF. Provided critical revisions: MJ FD RH AA AS.
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009.
CA Cancer J Clin 59: 225–249.
2. Sasco AJ, Lowenfels AB, Pasker-de Jong P (1993) Review article: epidemiology
of male breast cancer. A meta-analysis of published case-control studies and
discussion of selected aetiological factors. Int J Cancer 53: 538–549.
3. Weiss JR, Moysich KB, Swede H (2005) Epidemiology of male breast cancer.
Cancer Epidemiol Biomarkers Prev 14: 20–26.
4. Gomez-Raposo C, Zambrana Tevar F, Sereno Moyano M, Lopez Gomez M,
Casado E (2010) Male breast cancer. Cancer Treat Rev 36: 451–457.
5. Thompson D, Easton D (2001) Variation in cancer risks, by mutation position,
in BRCA2 mutation carriers. Am J Hum Genet 68: 410–419.
6. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A,
et al. (2002) Low-penetrance susceptibility to breast cancer due to
CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat
Genet 31: 55–59.
7. Fletcher O, Houlston RS (2010) Architecture of inherited susceptibility to
common cancer. Nat Rev Cancer 10: 353–361.
8. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, et al. (2009)
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat
Genet 41: 585–590.
9. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007)
Genome-wide association study identifies novel breast cancer susceptibility loci.
Nature 447: 1087–1093.
10. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, et al. (2011) Novel Breast
Cancer Susceptibility Locus at 9q31.2: Results of a Genome-Wide Association
Study. J Natl Cancer Inst.
11. Milne RL, Benitez J, Nevanlinna H, Heikkinen T, Aittomaki K, et al. (2009)
Risk of estrogen receptor-positive and -negative breast cancer and single-
nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst 101: 1012–1018.
12. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, et al. (2008)
Common variants on chromosome 5p12 confer susceptibility to estrogen
receptor-positive breast cancer. Nat Genet 40: 703–706.
13. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, et al. (2009) A
multistage genome-wide association study in breast cancer identifies two new risk
alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41: 579–584.
14. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, et al. (2010) Genome-
wide association study identifies five new breast cancer susceptibility loci. Nat
Genet 42: 504–507.
15. Eisen T, Matakidou A, Houlston R (2008) Identification of low penetrance
alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study
(GELCAPS). BMC Cancer 8: 244.
16. Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy-
Weinberg equilibrium. Am J Hum Genet 76: 887–893.
17. Team RDC (2010) R: A language and envirnoment for statistical computing.
2.11.1 ed. Vienna: R Foundation for Statistical Computing.
18. Clark GM, Osborne CK, McGuire WL (1984) Correlations between estrogen
receptor, progesterone receptor, and patient characteristics in human breast
cancer. J Clin Oncol 2: 1102–1109.
19. Willsher PC, Leach IH, Ellis IO, Bell JA, Elston CW, et al. (1997) Male breast
cancer: pathological and immunohistochemical features. Anticancer Res 17:
2335–2338.
20. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, et al. (2008)
Heterogeneity of breast cancer associations with five susceptibility loci by clinical
and pathological characteristics. PLoS Genet 4: e1000054. doi:10.1371/
journal.pgen.1000054.
21. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, et al. (2010) A
locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is
associated with hormone receptor-negative breast cancer in the general
population. Nat Genet 42: 885–892.
Common Genetic Variants and Male Breast Cancer
PLoS Genetics | www.plosgenetics.org 4 September 2011 | Volume 7 | Issue 9 | e1002290
         
